| Oct 14 |
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
|
| Oct 9 |
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
|
| Oct 2 |
Bausch + Lomb price target raised to $19 from $17 at Evercore ISI
|
| Oct 1 |
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
|
| Sep 22 |
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
|
| Sep 19 |
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
|
| Sep 19 |
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
|
| Sep 18 |
Bausch & Lomb may be worth about $28 a share in takeover - analyst
|
| Sep 18 |
Biggest stock movers Wednesday: SMCI, BLCO, LUNR, CWST, and more
|
| Sep 18 |
Bausch & Lomb gains after report of PE interest in takeover
|
